|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 95.89 USD | -1.30% |
|
+5.90% | +20.83% |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 29TCr | 32TCr | 36TCr | 37TCr | 40TCr | |||||
Total Revenues | 29TCr | 32TCr | 36TCr | 37TCr | 40TCr | |||||
Cost of Goods Sold, Total | 24TCr | 27TCr | 30TCr | 32TCr | 35TCr | |||||
Gross Profit | 5.08TCr | 5.35TCr | 5.33TCr | 4.92TCr | 5.31TCr | |||||
Selling General & Admin Expenses, Total | 3.71TCr | 3.8TCr | 3.92TCr | 4.12TCr | 4.31TCr | |||||
Other Operating Expenses, Total | 3.71TCr | 3.8TCr | 3.92TCr | 4.12TCr | 4.31TCr | |||||
Operating Income | 1.38TCr | 1.54TCr | 1.41TCr | 801.9Cr | 1TCr | |||||
Interest Expense, Total | -250.3Cr | -228.7Cr | -265.8Cr | -295.8Cr | -311.9Cr | |||||
Interest And Investment Income | 119.9Cr | 84Cr | 115.3Cr | 215.3Cr | 223.3Cr | |||||
Net Interest Expenses | -130.4Cr | -144.9Cr | -150.5Cr | -80Cr | -89Cr | |||||
Other Non Operating Income (Expenses) | -40L | -40L | -60L | -50L | -50L | |||||
EBT, Excl. Unusual Items | 1.25TCr | 1.4TCr | 1.26TCr | 720.9Cr | 912.8Cr | |||||
Restructuring Charges | -135.8Cr | - | -55Cr | -120.9Cr | -9.3Cr | |||||
Merger & Related Restructuring Charges | -13Cr | - | -49Cr | -24Cr | -12Cr | |||||
Impairment of Goodwill | -43Cr | - | - | - | -572.5Cr | |||||
Gain (Loss) On Sale Of Assets | - | -253.3Cr | -35Cr | - | 48Cr | |||||
Asset Writedown | - | - | - | - | - | |||||
Legal Settlements | 26Cr | -580.3Cr | - | -10Cr | -154Cr | |||||
Other Unusual Items | -39Cr | - | - | 49Cr | - | |||||
EBT, Incl. Unusual Items | 1.04TCr | 562.8Cr | 1.12TCr | 614.8Cr | 213.6Cr | |||||
Income Tax Expense | 252.2Cr | 146.3Cr | 280.5Cr | 156.2Cr | 41Cr | |||||
Earnings From Continuing Operations | 789.8Cr | 416.5Cr | 836.8Cr | 458.6Cr | 172.8Cr | |||||
Earnings Of Discontinued Operations | - | - | - | - | - | |||||
Net Income to Company | 789.8Cr | 416.5Cr | 836.8Cr | 458.6Cr | 172.8Cr | |||||
Minority Interest | 1.2Cr | -1.6Cr | -2.4Cr | 2.8Cr | 4Cr | |||||
Net Income - (IS) | 791Cr | 414.9Cr | 834.4Cr | 461.4Cr | 176.8Cr | |||||
Preferred Dividend and Other Adjustments | - | - | - | - | - | |||||
Net Income to Common Incl Extra Items | 791Cr | 414.9Cr | 834.4Cr | 461.4Cr | 176.8Cr | |||||
Net Income to Common Excl. Extra Items | 791Cr | 414.9Cr | 834.4Cr | 461.4Cr | 176.8Cr | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 6 | 3.16 | 6.49 | 3.66 | 1.4 | |||||
Basic EPS - Continuing Operations | 6 | 3.16 | 6.49 | 3.66 | 1.4 | |||||
Basic Weighted Average Shares Outstanding | 131.9Cr | 131.2Cr | 128.5Cr | 125.9Cr | 126.7Cr | |||||
Net EPS - Diluted | 5.95 | 3.14 | 6.47 | 3.66 | 1.39 | |||||
Diluted EPS - Continuing Operations | 5.95 | 3.14 | 6.47 | 3.66 | 1.39 | |||||
Diluted Weighted Average Shares Outstanding | 132.9Cr | 132.3Cr | 129Cr | 126.2Cr | 127.1Cr | |||||
Normalized Basic EPS | 5.92 | 6.64 | 6.09 | 3.6 | 4.53 | |||||
Normalized Diluted EPS | 5.87 | 6.58 | 6.07 | 3.59 | 4.52 | |||||
Dividend Per Share | 2 | 2.2 | 2.42 | 2.66 | 2.66 | |||||
Payout Ratio | 33.19 | 70.06 | 37.54 | 73.1 | 192.14 | |||||
American Depositary Receipts Ratio (ADR) | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | |||||
Supplemental Items | ||||||||||
EBITDA | 1.83TCr | 1.97TCr | 1.84TCr | 1.26TCr | 1.46TCr | |||||
EBITA | 1.6TCr | 1.72TCr | 1.6TCr | 1TCr | 1.2TCr | |||||
EBIT | 1.38TCr | 1.54TCr | 1.41TCr | 801.9Cr | 1TCr | |||||
EBITDAR | 2.15TCr | 2.28TCr | 2.16TCr | 1.56TCr | 1.76TCr | |||||
Total Revenues (As Reported) | 29TCr | 32TCr | 36TCr | 37TCr | 40TCr | |||||
Effective Tax Rate - (Ratio) | 24.2 | 26 | 25.11 | 25.41 | 19.1 | |||||
Current Domestic Taxes | 295Cr | 353.8Cr | 348.1Cr | 213.4Cr | 19Cr | |||||
Current Foreign Taxes | - | - | - | - | 11Cr | |||||
Total Current Taxes | 295Cr | 353.8Cr | 348.1Cr | 213.4Cr | 31Cr | |||||
Deferred Domestic Taxes | -43Cr | -207.5Cr | -68Cr | -57Cr | 10Cr | |||||
Total Deferred Taxes | -43Cr | -207.5Cr | -68Cr | -57Cr | 10Cr | |||||
Normalized Net Income | 780.51Cr | 871.15Cr | 782.72Cr | 453.36Cr | 574.5Cr | |||||
Interest Capitalized | - | - | - | - | - | |||||
Interest on Long-Term Debt | 253.7Cr | 228.7Cr | 7.3Cr | 7.1Cr | 6.9Cr | |||||
Non-Cash Pension Expense | -19Cr | -17Cr | -9.4Cr | -10Cr | -12Cr | |||||
Supplemental Operating Expense Items | ||||||||||
Advertising Expense | 52Cr | 74Cr | 98Cr | 99Cr | 97Cr | |||||
Selling and Marketing Expenses | 52Cr | 74Cr | 98Cr | 99Cr | 97Cr | |||||
Net Rental Expense, Total | 320.7Cr | 315.5Cr | 312.6Cr | 302.4Cr | 301.6Cr | |||||
Imputed Operating Lease Interest Expense | 80Cr | 79Cr | 89Cr | 88Cr | 92Cr | |||||
Imputed Operating Lease Depreciation | 240.95Cr | 236.82Cr | 224.04Cr | 214.22Cr | 209.19Cr | |||||
Stock-Based Comp., Other (Total) | 48Cr | 45Cr | 59Cr | 54Cr | 54Cr | |||||
Total Stock-Based Compensation | 48Cr | 45Cr | 59Cr | 54Cr | 54Cr |
- Stock Market
- Equities
- CVS Stock
- Financials CVS Health Corporation
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















